Share on LinkedInShare on LinkedIn

ARTICLE · 31 AUGUST 2015

Australian Competition and Consumer Commission focuses on the pharmaceutical industry

The case ACCC v Pfizer provides insights for the pharmaceutical industry on competition and generic defensive strategies.

AustraliaAntitrust/Competition Law

The case ACCC v Pfizer provides insights for the pharmaceutical industry on generic defensive strategies

Introduction

This article provides insights and tips for the pharmaceutical industry arising from the case of Australian Competition and Consumer Commission v Pfizer Australia Pty Ltd.1 Until May 2012, Pfizer held the patent for a cholesterol drug known as atorvastatin. Pfizer marketed atorvasatin under the brand Lipitor. Lipitor was one of Pfizer's most profitable drugs.

In anticipation of the upcoming expiry of its patent for atorvastatin, Pfizer implemented a new distribution model and sales platform. The Australian Competition and Consumer Commission (the ACCC) alleged that in executing this new strategy, Pfizer misused its market power and engaged in exclusive dealing in contravention of the Competition and Consumer Act 2010 (the Act).

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from